These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37178250)

  • 21. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes of drug-resistance of Pseudomonas aeruginosa in pediatric intensive care unit].
    Wang LJ; Sun Y; Song WL; Zhang ZJ; Liu CF
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):657-63. PubMed ID: 23158814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of
    Wang L; Zhang X; Zhou X; Yang F; Guo Q; Wang M
    Microbiol Spectr; 2023 Jun; 11(3):e0093223. PubMed ID: 37199669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An α-Lipoic acid derivative, and anti-ROS agent, prevents the acquisition of multi-drug resistance in clinical isolates of Pseudomonas aeruginosa.
    Hayakawa S; Kawamura M; Sato T; Hirano T; Kikuchi T; Watanabe A; Fujimura S
    J Infect Chemother; 2019 Jan; 25(1):28-33. PubMed ID: 30396822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced efficacy of putative efflux pump inhibitor/antibiotic combination treatments versus MDR strains of Pseudomonas aeruginosa in a Galleria mellonella in vivo infection model.
    Adamson DH; Krikstopaityte V; Coote PJ
    J Antimicrob Chemother; 2015 Aug; 70(8):2271-8. PubMed ID: 25921513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
    Griffith DC; Corcoran E; Lofland D; Lee A; Cho D; Lomovskaya O; Dudley MN
    Antimicrob Agents Chemother; 2006 May; 50(5):1628-32. PubMed ID: 16641428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa.
    López-Pérez M; Haro-Moreno JM; Molina-Pardines C; Ventero MP; Rodríguez JC
    mSphere; 2021 Dec; 6(6):e0083621. PubMed ID: 34817240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients.
    Zhao L; Li X; He X; Jian L
    BMC Pharmacol Toxicol; 2020 Mar; 21(1):20. PubMed ID: 32131897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diversity of β-lactamases produced by imipenem resistant, Pseudomonas aeruginosa isolates from the bloodstream.
    Najar Peerayeh S; Pirhajati Mahabadi R; Pakbaten Toupkanlou S; Siadat SD
    Burns; 2014 Nov; 40(7):1360-4. PubMed ID: 24513132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.
    Lomovskaya O; Warren MS; Lee A; Galazzo J; Fronko R; Lee M; Blais J; Cho D; Chamberland S; Renau T; Leger R; Hecker S; Watkins W; Hoshino K; Ishida H; Lee VJ
    Antimicrob Agents Chemother; 2001 Jan; 45(1):105-16. PubMed ID: 11120952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of ST463
    Zhu Y; Kang Y; Zhang H; Yu W; Zhang G; Zhang J; Kang W; Duan S; Xu Y; Yang Q
    Microbiol Spectr; 2023 Aug; 11(4):e0010523. PubMed ID: 37314344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa.
    Fournier D; Richardot C; Müller E; Robert-Nicoud M; Llanes C; Plésiat P; Jeannot K
    J Antimicrob Chemother; 2013 Aug; 68(8):1772-80. PubMed ID: 23587654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections.
    Horner C; Mushtaq S; Livermore DM;
    J Antimicrob Chemother; 2019 Jul; 74(7):1940-1944. PubMed ID: 31032858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
    Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Rossi F; Zumiotti AV
    Infect Control Hosp Epidemiol; 2009 May; 30(5):487-90. PubMed ID: 19335227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to imipenem in Pseudomonas aeruginosa.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1995 Dec; 36(6):1037-41. PubMed ID: 8821603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant Pseudomonas aeruginosa isolated from patients with bloodstream infections in Taiwan.
    Kao CY; Chen SS; Hung KH; Wu HM; Hsueh PR; Yan JJ; Wu JJ
    BMC Microbiol; 2016 Jun; 16(1):107. PubMed ID: 27296461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
    Louie A; Grasso C; Bahniuk N; Van Scoy B; Brown DL; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2646-54. PubMed ID: 20368395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of mexAB-oprM and mexXY (-oprA) efflux operons in antibiotic resistance of clinical Pseudomonas aeruginosa isolates in Tabriz, Iran.
    Goli HR; Nahaei MR; Rezaee MA; Hasani A; Samadi Kafil H; Aghazadeh M; Sheikhalizadeh V
    Infect Genet Evol; 2016 Nov; 45():75-82. PubMed ID: 27562333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa.
    Gomis-Font MA; Cabot G; Sánchez-Diener I; Fraile-Ribot PA; Juan C; Moya B; Zamorano L; Oliver A
    J Antimicrob Chemother; 2020 Sep; 75(9):2508-2515. PubMed ID: 32514525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.